seri unfortun delay chmp slow
ptla commerci effort europ
bottom line announc result trend opinion
committe medicin product human use chmp
andexanet betrixaban even first posit
delay approv latter threaten viabil betrixaban
eu lower target price reiter
outperform rate stock trade current
ep estim decreas
target price base dcf valuat risk target/r
includ delay andexanet approv issu betrixaban us
launch highli competit data xarelto marin trial
blow betrixaban chmp view case betrixaban
optimist fda offer neg trend vote make
approv highli unlik absenc addit data though
possibl trend could revers anoth member class
succeed popul marin trial bayer/jnj xarelto
read cautious remov eu sale betrixaban
model
mix outcom andexanet chmp issu posit trend
vote andexanet addit data request push back potenti
approv remov eu sale model slow
eu ramp andexanet due lack addit sale support
follow ptla decis divert resourc plan eu betrixaban
launch support us launch instead
impact strategi view increas likelihood pursu
licens strategi product ex-u continu view
potenti interest partnership acquisit
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
us million unless otherwis state
portola biopharmaceut compani focus
develop commerci novel therapeut
area thrombosi hematolog disord inflamm
patient current limit approv treatment
price feb rate outperform target price analyst vamil divan
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
cash-flow financ activ
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
 close
blue sky valuat base probability-adjust
dcf driven combin global sale bevyxxa andexxa
exceed peak
grey sky valuat base probability-adjust
dcf driven combin sale bevyxxa andexxa peak
compani mention price
